Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects
- Registration Number
- NCT01247103
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to assess the safety, tolerability and pharmacokinetics of AZD4316 following oral administration of single and multiple doses to healthy volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 128
Inclusion Criteria
- Healthy male and female subjects aged 18 to 50 years with suitable veins for cannulation or repeated venepuncture.
- Female subjects must not be pregnant, must not be lactating and must be of non-child-bearing potential (i.e. they must be post-menopausal or surgically sterile)
- Male subjects should be willing to use barrier contraception i.e. condoms and spermicide, from the day of dosing until at least 3 months after dosing with the investigational product
- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
- Subjects who are healthy as determined by pre study medical history, physical examination, 12-Lead ECG
Exclusion Criteria
- History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG, including changes that may interfere with the interpretation of QTcF interval changes.
- Current smokers, those who have smoked or used nicotine products within the previous three months.
- History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4316.
- Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part A: single ascending dose Placebo AZD4316: single oral dose, with 1 group with/without food Part B: multiple ascending dose Placebo AZD4316: multiple oral doses Part A: single ascending dose AZD4316 AZD4316: single oral dose, with 1 group with/without food Part B: multiple ascending dose AZD4316 AZD4316: multiple oral doses
- Primary Outcome Measures
Name Time Method Assessment of laboratory variables and physical examinations from screening period to follow-up Frequent assessments will be made for each subject from the screening period to follow up
Assessment of Electrocardiogram (ECG) variables from screening period to follow-up Frequent assessments will be made for each subject from the screening period to follow up
Number of participants with adverse events from screening period to follow-up Assesment of vital signs (blood pressure, pulse and temperature) from screening period to follow-up Frequent assessments will be made for each subject from the screening period to follow up
- Secondary Outcome Measures
Name Time Method Pharmacokinetic variables of AZD4316 by assessment of drug concentrations in plasma and urine Serial blood samples and urine collection for PK evaluation throughout the period of admission and up to the time of the follow-up visit
Trial Locations
- Locations (1)
Research Site
🇬🇧London, United Kingdom